TY - JOUR
T1 - Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer
T2 - Analysis of Safety and Efficacy for Patients With Renal Impairment
AU - Yoneshima, Yasuto
AU - Morita, Satoshi
AU - Ando, Masahiko
AU - Nakamura, Atsushi
AU - Iwasawa, Shunichiro
AU - Yoshioka, Hiroshige
AU - Goto, Yasuhiro
AU - Takeshita, Masafumi
AU - Harada, Toshiyuki
AU - Hirano, Katsuya
AU - Oguri, Tetsuya
AU - Kondo, Masashi
AU - Miura, Satoru
AU - Hosomi, Yukio
AU - Kato, Terufumi
AU - Kubo, Toshio
AU - Kishimoto, Junji
AU - Yamamoto, Nobuyuki
AU - Nakanishi, Yoichi
AU - Okamoto, Isamu
N1 - Publisher Copyright:
© 2022
PY - 2022/11
Y1 - 2022/11
N2 - Background: Renal impairment can affect treatment tolerability and outcome in individuals with cancer. We aimed to assess the safety and efficacy of nab-paclitaxel for previously treated patients with advanced non–small cell lung cancer (NSCLC) and renal impairment enrolled in a phase 3 trial of nab-paclitaxel vs. docetaxel. Patients and Methods: Previously treated NSCLC patients were randomly allocated (1:1) to receive docetaxel (60 mg/m²) on day 1 or nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 of a 21-day cycle. Safety and efficacy outcomes of treatment were evaluated according to renal function. Results: Among the 503 patients enrolled in the phase 3 trial, 17.3% had moderate renal impairment (creatinine clearance of ≤50 mL/min, n = 49 for docetaxel and n = 38 for nab-paclitaxel) and 53.1% had mild renal impairment (creatinine clearance of >50 to ≤80 mL/min, n = 133 for docetaxel and n = 134 for nab-paclitaxel). For patients with renal impairment, the incidence of febrile neutropenia was lower in the nab-paclitaxel group than in the docetaxel group. The difference in treatment efficacy for nab-paclitaxel vs. docetaxel among patients with moderate or mild renal impairment was similar to that among the overall study population. Conclusion: Nab-paclitaxel was found to be tolerable and beneficial for previously treated patients with advanced NSCLC and mild or moderate renal impairment.
AB - Background: Renal impairment can affect treatment tolerability and outcome in individuals with cancer. We aimed to assess the safety and efficacy of nab-paclitaxel for previously treated patients with advanced non–small cell lung cancer (NSCLC) and renal impairment enrolled in a phase 3 trial of nab-paclitaxel vs. docetaxel. Patients and Methods: Previously treated NSCLC patients were randomly allocated (1:1) to receive docetaxel (60 mg/m²) on day 1 or nab-paclitaxel (100 mg/m²) on days 1, 8, and 15 of a 21-day cycle. Safety and efficacy outcomes of treatment were evaluated according to renal function. Results: Among the 503 patients enrolled in the phase 3 trial, 17.3% had moderate renal impairment (creatinine clearance of ≤50 mL/min, n = 49 for docetaxel and n = 38 for nab-paclitaxel) and 53.1% had mild renal impairment (creatinine clearance of >50 to ≤80 mL/min, n = 133 for docetaxel and n = 134 for nab-paclitaxel). For patients with renal impairment, the incidence of febrile neutropenia was lower in the nab-paclitaxel group than in the docetaxel group. The difference in treatment efficacy for nab-paclitaxel vs. docetaxel among patients with moderate or mild renal impairment was similar to that among the overall study population. Conclusion: Nab-paclitaxel was found to be tolerable and beneficial for previously treated patients with advanced NSCLC and mild or moderate renal impairment.
UR - http://www.scopus.com/inward/record.url?scp=85138019266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138019266&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2022.08.011
DO - 10.1016/j.cllc.2022.08.011
M3 - Article
C2 - 36114096
AN - SCOPUS:85138019266
SN - 1525-7304
VL - 23
SP - 585
EP - 592
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 7
ER -
